[
    [
        {
            "time": "2019-06-13",
            "original_text": "After Hours Most Active for Jun 13, 2019: GE, HAL, CZR, PG, LVS, LLY, HPE, AAPL, FLEX, CMCSA, CINF, ZNGA",
            "features": {
                "keywords": [
                    "active",
                    "GE",
                    "LLY",
                    "AAPL"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "technology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "After Hours Most Active for Jun 13, 2019: GE, HAL, CZR, PG, LVS, LLY, HPE, AAPL, FLEX, CMCSA, CINF, ZNGA",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 2
            }
        },
        {
            "time": "2019-06-13",
            "original_text": "Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s",
            "features": {
                "keywords": [
                    "M&A",
                    "Amgen",
                    "Biogen",
                    "Gilead",
                    "Novo Nordisk"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-06-01",
            "original_text": "3 Top Diabetes Stocks to Watch in June",
            "features": {
                "keywords": [
                    "diabetes",
                    "stocks",
                    "watch"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 Top Diabetes Stocks to Watch in June",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-06-13",
            "original_text": "Thursday Sector Laggards: Healthcare, Utilities",
            "features": {
                "keywords": [
                    "laggards",
                    "healthcare",
                    "utilities"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "utilities"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Thursday Sector Laggards: Healthcare, Utilities",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-06-13",
            "original_text": "NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag",
            "features": {
                "keywords": [
                    "NuCana",
                    "orphan drug",
                    "cancer"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-06-13",
            "original_text": "Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Xeljanz",
                    "RA",
                    "study"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-06-13",
            "original_text": "Eli Lilly Broke Below the 200-Day Average to Change the Narrative to Bearish",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "200-day average",
                    "bearish"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly Broke Below the 200-Day Average to Change the Narrative to Bearish",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]